Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrasentan in type 2 diabetes with nephropathy
jRCT2080222156Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing Atrasentan once daily with Placebo once daily (2 arms). Started Jul 2013; status: completed.
02
Drugs
atrasentan
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080222156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222156.